Nexoplex Bio is committed to providing the media with accurate and timely information.
After emerging from Chapter 11 bankruptcy, hiring a new management team and a dedicated new team of scientists, Gritstone bio is changing its name to Nexoplex bio. This change is reflective of new energy and focus on the development of our portfolio of bispecific antibodies. Watch for more exciting updates as our team progresses our portfolio of bispecifics to provide treatments for […]
Gritstone Bio, Inc., a biotechnology company developing next-generation immunotherapies targeting tumor-specific peptide–HLA (pMHC) complexes, today announced the issuance of two patents in 2025 expanding the company’s international intellectual property portfolio.
Gritstone Bio, Inc., a biotechnology company developing next-generation immunotherapies targeting tumor-specific peptide–HLA complexes, today announced its acceptance into MBC BioLabs, one of the Bay Area’s leading incubators for early-stage life science companies.